Key statistics
On Friday, Inventiva SA (6IV:DEU) closed at 2.43, 70.77% above the 52 week low of 1.42 set on Oct 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.40 |
---|---|
High | 2.46 |
Low | 2.37 |
Bid | 2.42 |
Offer | 2.46 |
Previous close | 2.40 |
Average volume | 920.80 |
---|---|
Shares outstanding | 87.08m |
Free float | 76.24m |
P/E (TTM) | -- |
Market cap | 211.60m EUR |
EPS (TTM) | -2.08 EUR |
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Announcements
- Inventiva annonce la recommandation positive du cinquième DMC de l’étude clinique NATiV3 Phase 3 avec lanifibranor dans la MASH
- Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
- Inventiva annonce un abstract « late breaker » sur l’essai clinique de Phase 2, LEGEND, combinant lanifibranor et empagliflozine, lors du Liver Meeting™ 2024 organisé par l’AASLD
- Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
- Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
- Inventiva annonce la mise à disposition d'un prospectus dans le cadre de son financement par l’émission d’actions ordinaires et de bons de souscription d’action préfinancés
- Inventiva publie son Rapport Financier Semestriel 2024 – Modalités de mise à disposition ou de consultation
- Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
- Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
- Inventiva annonce un financement allant jusqu’à 348 millions d'euros afin d’avancer l’étude NATiV3 de Phase 3 dans la MASH
More ▼